Alumis Inc (ALMS)

$27.28 -0.82 (-2.92%)
Market Cap 3.58B
Revenue (ttm) 24.05M
Net Income (ttm) -243.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,011.77%
Debt to Equity Ratio 0.00
Volume 1,992,300
Avg Vol 1,373,766
Day's Range N/A - N/A
Shares Out 127.49M
Stochastic %K 31%
Beta -0.73
Analysts Strong Sell
Price Target $40.11

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibo...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
laaarsas
laaarsas Jul. 10 at 3:13 PM
$ALMS Why slurping today?
0 · Reply
Quantumup
Quantumup Jul. 9 at 4:05 PM
Stifel reiterated $ALMS Buy-$44 and Provided Its Thoughts and PT Analysis on Upcoming SLE Data [3Q26]—Said It Thinks Study Will Likely Be Successful. $BMY $AUPH GSK AZN RHHBY JNJ UCB BIIB KYTX NVS Here's what Stifel said in its note: https://x.com/Quantumup1/status/2075249640333508661?s=20
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 9 at 3:23 AM
$TERN $ALMS $PRME $ALT $CAPR Alright folks. You saw AlMS, TERN and CApR MAKE WILD RUNS IN 8 MONTHS. get ready for the next runs. $PRME Just formed a golden cross. Won huge legal battle which had a lot of overhang and drove price from upper teens to below $3. Continues to be the highest asymetric play in gene editing as the technology is the cleanest. In human proof of concept is already proven and published. This will make those with high conviction big gains. $ALT all the waiting will be paying off within the next 6 months. $CAPR dropped back down to let me buy the dip. 60 dollars PT. Nfa Gltya.
0 · Reply
Quantumup
Quantumup Jul. 8 at 4:19 PM
Cantor reiterated an Overweight rating on $ALMS. $GSK $AUPH AZN RHHBY ABBV - APGE ORKA JNJ - PTGX BMY TAK Cantor said ~~ We recently caught up with ALMS management to discuss envudeucitinib's (envu', next-gen TYK2 inhibitor) upcoming Phase 2b readout in systemic lupus erythematosus (SLE). As a reminder, data from Alumis's LUMIS study are expected in the August/ September timeframe, and if positive this trial could serve as a pivotal study. Investor interest in this milestone is ramping up as data nears. Alumis is planning to host a KOL webinar in advance of the data release to better frame potential trial outcomes and the opportunity.
0 · Reply
SirBensonbot
SirBensonbot Jul. 8 at 12:23 AM
$ALMS 10%+ tmmrw
0 · Reply
SirBensonbot
SirBensonbot Jul. 7 at 11:25 PM
$ALMS long
0 · Reply
laaarsas
laaarsas Jul. 7 at 8:27 PM
$ALMS Why melting up?
0 · Reply
droog_botski
droog_botski Jul. 7 at 7:54 PM
$ALMS Maybe we have been going up lately following PTGX as JNJ says icotyde can do over 10 billion peak.
0 · Reply
fda_tracker
fda_tracker Jul. 2 at 2:46 PM
$ALMS Phase 2 trial w/est Jul completion date NCT05966480: https://www.clinicaltrials.gov/study/NCT05966480 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
droog_botski
droog_botski Jun. 30 at 5:22 PM
$ALMS You would think some kind of good news is coming here...
0 · Reply
Latest News on ALMS
Alumis management to meet with Cantor

2026-06-26T20:25:16.000Z - 18 days ago

Alumis management to meet with Cantor

Alumis rises 10.3%

2026-06-12T16:09:42.000Z - 4 weeks ago

Alumis rises 10.3%

Alumis price target raised to $40 from $38 at Chardan

2026-05-19T12:01:10.000Z - 2 months ago

Alumis price target raised to $40 from $38 at Chardan

Alumis Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 2 months ago

Alumis Proxy statement: Proxy filing

Alumis Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 2 months ago

Alumis Proxy statement: Proxy filing

Alumis price target raised to $39 from $38 at Morgan Stanley

2026-05-15T12:49:04.000Z - 2 months ago

Alumis price target raised to $39 from $38 at Morgan Stanley

Alumis price target raised to $51 from $49 at Wells Fargo

2026-05-15T11:13:04.000Z - 2 months ago

Alumis price target raised to $51 from $49 at Wells Fargo

Alumis Slides: Corporate presentation

May 15, 2026, 7:00 AM EDT - 2 months ago

Alumis Slides: Corporate presentation

Alumis price target raised to $34 from $32 at Guggenheim

2026-05-15T10:58:47.000Z - 2 months ago

Alumis price target raised to $34 from $32 at Guggenheim

Alumis downgraded to Neutral from Buy at H.C. Wainwright

2026-05-15T10:10:10.000Z - 2 months ago

Alumis downgraded to Neutral from Buy at H.C. Wainwright

Alumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year

2026-05-14T21:23:34.000Z - 2 months ago

Alumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

May 14, 2026, 4:05 PM EDT - 2 months ago

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

Alumis Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 2 months ago

Alumis Earnings release: Q1 2026

Alumis Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 2 months ago

Alumis Quarterly report: Q1 2026

Alumis falls -16.1%

2026-03-30T16:08:52.000Z - 3 months ago

Alumis falls -16.1%

Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James

2026-03-30T15:50:16.000Z - 3 months ago

Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James

JNJ TAK

Alumis price target raised to $55 from $50 at Oppenheimer

2026-03-30T11:51:26.000Z - 3 months ago

Alumis price target raised to $55 from $50 at Oppenheimer

JNJ TAK

Alumis price target lowered to $25 from $40 at H.C. Wainwright

2026-03-30T10:15:07.000Z - 3 months ago

Alumis price target lowered to $25 from $40 at H.C. Wainwright

Alumis Transcript: Study update

Mar 29, 2026, 7:00 PM EDT - 3 months ago

Alumis Transcript: Study update

Alumis Press release: Study update

Mar 29, 2026, 7:00 PM EDT - 3 months ago

Alumis Press release: Study update

Alumis Slides: Study update

Mar 29, 2026, 7:00 PM EDT - 3 months ago

Alumis Slides: Study update

Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib

2026-03-29T14:30:06.000Z - 3 months ago

Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib

Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Mar 28, 2026, 1:30 PM EDT - 3 months ago

Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Alumis price target raised to $38 from $33 at Morgan Stanley

2026-03-20T10:51:00.000Z - 4 months ago

Alumis price target raised to $38 from $33 at Morgan Stanley

Alumis files automatic mixed securities shelf

2026-03-19T21:05:19.000Z - 4 months ago

Alumis files automatic mixed securities shelf

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Mar 19, 2026, 4:05 PM EDT - 4 months ago

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Alumis Annual report: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 4 months ago

Alumis Annual report: Q4 2025

Alumis Earnings release: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 4 months ago

Alumis Earnings release: Q4 2025

Alumis Slides: Corporate presentation

Mar 19, 2026, 7:00 AM EDT - 4 months ago

Alumis Slides: Corporate presentation

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Mar 18, 2026, 8:00 AM EDT - 4 months ago

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Alumis initiated with a Strong Buy at Raymond James

2026-03-10T20:10:32.000Z - 4 months ago

Alumis initiated with a Strong Buy at Raymond James

Alumis Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 10:40 AM EDT - 4 months ago

Alumis Transcript: Leerink Global Healthcare Conference 2026

Alumis to Present at the Leerink Partners Global Healthcare Conference

Mar 2, 2026, 8:05 AM EST - 4 months ago

Alumis to Present at the Leerink Partners Global Healthcare Conference

Alumis Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 3:20 PM EST - 4 months ago

Alumis Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Alumis initiated with a Buy at Stifel

2026-02-24T21:46:41.000Z - 5 months ago

Alumis initiated with a Buy at Stifel

Alumis Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 9:00 AM EST - 5 months ago

Alumis Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Alumis to Participate in Upcoming February Investor Conferences

Feb 5, 2026, 8:05 AM EST - 5 months ago

Alumis to Participate in Upcoming February Investor Conferences

Alumis rises 7.8%

2026-02-02T15:05:49.000Z - 5 months ago

Alumis rises 7.8%

Alumis initiated with a Buy at Chardan

2026-01-21T09:40:27.000Z - 6 months ago

Alumis initiated with a Buy at Chardan

Alumis rises 10.2%

2026-01-14T17:07:36.000Z - 6 months ago

Alumis rises 10.2%

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 9, 2026, 4:05 PM EST - 6 months ago

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Jan 7, 2026, 10:52 PM EST - 6 months ago

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Alumis Announces Proposed Public Offering of Common Stock

Jan 6, 2026, 4:12 PM EST - 6 months ago

Alumis Announces Proposed Public Offering of Common Stock

Alumis Transcript: Study Result

Jan 6, 2026, 8:00 AM EST - 6 months ago

Alumis Transcript: Study Result

Alumis Press release: Study Result

Jan 6, 2026, 8:00 AM EST - 6 months ago

Alumis Press release: Study Result

Alumis Slides: Study Result

Jan 6, 2026, 8:00 AM EST - 6 months ago

Alumis Slides: Study Result

Alumis skin disease drug meets main goal of two late-stage trials

Jan 6, 2026, 7:07 AM EST - 6 months ago

Alumis skin disease drug meets main goal of two late-stage trials

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Jan 6, 2026, 7:00 AM EST - 6 months ago

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Jan 5, 2026, 5:00 PM EST - 6 months ago

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 13, 2025, 4:15 PM EST - 8 months ago

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis Quarterly report: Q3 2025

Nov 13, 2025, 4:00 PM EST - 8 months ago

Alumis Quarterly report: Q3 2025

Alumis Earnings release: Q3 2025

Nov 13, 2025, 4:00 PM EST - 8 months ago

Alumis Earnings release: Q3 2025

Alumis Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 2:00 PM EST - 8 months ago

Alumis Transcript: Stifel 2025 Healthcare Conference

Alumis Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 1:30 PM EST - 8 months ago

Alumis Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Alumis to Participate in Upcoming November Investor Conferences

Nov 4, 2025, 8:00 AM EST - 9 months ago

Alumis to Participate in Upcoming November Investor Conferences

Alumis Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 16, 2025, 12:30 PM EDT - 10 months ago

Alumis Transcript: Stifel Virtual Immunology and Inflammation Forum

Alumis Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 4:50 PM EDT - 11 months ago

Alumis Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Alumis Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 5, 2025, 9:30 AM EDT - 11 months ago

Alumis Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Alumis Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:45 AM EDT - 11 months ago

Alumis Transcript: Cantor Global Healthcare Conference 2025

Alumis Slides: Corporate Presentation

Sep 3, 2025, 8:00 AM EDT - 11 months ago

Alumis Slides: Corporate Presentation

Alumis to Participate in Upcoming September Investor Conferences

Aug 29, 2025, 7:00 AM EDT - 11 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 11 months ago

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Alumis Quarterly report: Q2 2025

Alumis Earnings release: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Alumis Earnings release: Q2 2025

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Jul 24, 2025, 7:30 AM EDT - 1 year ago

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Jul 14, 2025, 4:05 PM EDT - 1 year ago

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis Registration statement: Registration Filing

Jul 3, 2025, 8:00 AM EDT - 1 year ago

Alumis Registration statement: Registration Filing

Alumis Proxy statement: Proxy Filing

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Alumis Proxy statement: Proxy Filing

Alumis Proxy statement: Proxy Filing

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Alumis Proxy statement: Proxy Filing

Alumis Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 3:10 PM EDT - 1 year ago

Alumis Transcript: Jefferies Global Healthcare Conference 2025

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025, 4:15 PM EDT - 1 year ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 29, 2025, 7:55 AM EDT - 1 year ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 1 year ago

Alumis Completes Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 14, 2025, 4:05 PM EDT - 1 year ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Alumis Quarterly report: Q1 2025

Alumis Earnings release: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Alumis Earnings release: Q1 2025

Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 1 year ago

Alumis Stockholders Approve Merger with ACELYRIN

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 1 year ago

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Apr 16, 2025, 5:31 PM EDT - 1 year ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Apr 4, 2025, 4:34 PM EDT - 1 year ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 25, 2025, 2:30 AM EDT - 1 year ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis Annual report: Q4 2024

Mar 19, 2025, 4:00 PM EDT - 1 year ago

Alumis Annual report: Q4 2024

Alumis Earnings release: Q4 2024

Mar 19, 2025, 4:00 PM EDT - 1 year ago

Alumis Earnings release: Q4 2024

Alumis Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 10:40 AM EDT - 1 year ago

Alumis Transcript: Leerink’s Global Healthcare Conference 2025

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 8, 2025, 9:00 AM EST - 1 year ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:01 AM EST - 1 year ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Mar 4, 2025, 9:00 AM EST - 1 year ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 28, 2025, 9:08 AM EST - 1 year ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 27, 2025, 4:15 PM EST - 1 year ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 3:20 PM EST - 1 year ago

Alumis Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 4:45 PM EST - 1 year ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

Feb 7, 2025, 3:22 PM EST - 1 year ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Alumis Transcript: M&A Announcement

Feb 6, 2025, 5:00 PM EST - 1 year ago

Alumis Transcript: M&A Announcement

Alumis Press release: M&A Announcement

Feb 6, 2025, 5:00 PM EST - 1 year ago

Alumis Press release: M&A Announcement

Alumis Slides: M&A Announcement

Feb 6, 2025, 5:00 PM EST - 1 year ago

Alumis Slides: M&A Announcement

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Feb 6, 2025, 4:15 PM EST - 1 year ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 1 year ago

Alumis Strengthens Leadership Team with Key Appointments

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Nov 13, 2024, 4:05 PM EST - 1 year ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Alumis Quarterly report: Q3 2024

Alumis Earnings release: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Alumis Earnings release: Q3 2024

Alumis Transcript: Guggenheim's Inaugural Healthcare Innovation Conference

Nov 12, 2024, 2:00 PM EST - 1 year ago

Alumis Transcript: Guggenheim's Inaugural Healthcare Innovation Conference

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 27, 2024, 9:00 AM EDT - 1 year ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 10:55 AM EDT - 1 year ago

Alumis Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Aug 13, 2024, 4:05 PM EDT - 2 years ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Alumis Quarterly report: Q2 2024

Alumis Earnings release: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Alumis Earnings release: Q2 2024

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 29, 2024, 8:00 AM EDT - 2 years ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:58 PM EDT - 2 years ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Jun 28, 2024, 12:43 AM EDT - 2 years ago

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Alumis Announces Pricing of Initial Public Offering

Jun 27, 2024, 11:57 PM EDT - 2 years ago

Alumis Announces Pricing of Initial Public Offering

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Jun 24, 2024, 8:27 AM EDT - 2 years ago

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Alumis Registration statement: Registration Filing

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Alumis Registration statement: Registration Filing

Alumis eyes $300 million in proceeds in IPO

Jun 24, 2024, 7:18 AM EDT - 2 years ago

Alumis eyes $300 million in proceeds in IPO

laaarsas
laaarsas Jul. 10 at 3:13 PM
$ALMS Why slurping today?
0 · Reply
Quantumup
Quantumup Jul. 9 at 4:05 PM
Stifel reiterated $ALMS Buy-$44 and Provided Its Thoughts and PT Analysis on Upcoming SLE Data [3Q26]—Said It Thinks Study Will Likely Be Successful. $BMY $AUPH GSK AZN RHHBY JNJ UCB BIIB KYTX NVS Here's what Stifel said in its note: https://x.com/Quantumup1/status/2075249640333508661?s=20
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 9 at 3:23 AM
$TERN $ALMS $PRME $ALT $CAPR Alright folks. You saw AlMS, TERN and CApR MAKE WILD RUNS IN 8 MONTHS. get ready for the next runs. $PRME Just formed a golden cross. Won huge legal battle which had a lot of overhang and drove price from upper teens to below $3. Continues to be the highest asymetric play in gene editing as the technology is the cleanest. In human proof of concept is already proven and published. This will make those with high conviction big gains. $ALT all the waiting will be paying off within the next 6 months. $CAPR dropped back down to let me buy the dip. 60 dollars PT. Nfa Gltya.
0 · Reply
Quantumup
Quantumup Jul. 8 at 4:19 PM
Cantor reiterated an Overweight rating on $ALMS. $GSK $AUPH AZN RHHBY ABBV - APGE ORKA JNJ - PTGX BMY TAK Cantor said ~~ We recently caught up with ALMS management to discuss envudeucitinib's (envu', next-gen TYK2 inhibitor) upcoming Phase 2b readout in systemic lupus erythematosus (SLE). As a reminder, data from Alumis's LUMIS study are expected in the August/ September timeframe, and if positive this trial could serve as a pivotal study. Investor interest in this milestone is ramping up as data nears. Alumis is planning to host a KOL webinar in advance of the data release to better frame potential trial outcomes and the opportunity.
0 · Reply
SirBensonbot
SirBensonbot Jul. 8 at 12:23 AM
$ALMS 10%+ tmmrw
0 · Reply
SirBensonbot
SirBensonbot Jul. 7 at 11:25 PM
$ALMS long
0 · Reply
laaarsas
laaarsas Jul. 7 at 8:27 PM
$ALMS Why melting up?
0 · Reply
droog_botski
droog_botski Jul. 7 at 7:54 PM
$ALMS Maybe we have been going up lately following PTGX as JNJ says icotyde can do over 10 billion peak.
0 · Reply
fda_tracker
fda_tracker Jul. 2 at 2:46 PM
$ALMS Phase 2 trial w/est Jul completion date NCT05966480: https://www.clinicaltrials.gov/study/NCT05966480 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
droog_botski
droog_botski Jun. 30 at 5:22 PM
$ALMS You would think some kind of good news is coming here...
0 · Reply
Quantumup
Quantumup Jun. 29 at 11:16 AM
Citizens reitd $VRDN Mkt OP, $35 and said: Lumvoa (veli) approved by FDA with the expected differentiated label; we reiterate our Market Outperform rating and $35 risk-adjusted, DCF-derived price target on Viridian Therapeutics. $AMGN $ALMS IMVT - ROIV RHHBY TRML Citizens added—On Friday, the FDA approved Lumvoa (veligrotug) for the treatment of thyroid eye disease ahead of its June 30, 2026 PDUFA date. As expected, the label is inclusive of positive Phase 3 results for both active and chronic TED populations. The company anticipates immediate launch of Lumvoa and created ViridianCares, a patient support program, to enable broad access of Lumvoa. We continue to believe that the company is well-prepared to execute the launch of Lumvoa.
0 · Reply
Dcvfin
Dcvfin Jun. 27 at 5:36 PM
$ALMS whats the deal on this one? Chart looks good Drug seems like it works Insiders are buying FDA submission soon Is $40 after FDA approval realistic?
0 · Reply
JazzyJ03
JazzyJ03 Jun. 19 at 7:35 AM
$ALMS still a fave
0 · Reply
forprofit12
forprofit12 Jun. 16 at 5:39 PM
$ALMS doubled. 40% of my target position. Adding as funds become available.
1 · Reply
Spicy_Trade
Spicy_Trade Jun. 14 at 6:29 PM
Alumis Inc. ( $ALMS ) SpicyTrade - Daily Stock Analysis https://youtu.be/fFvavjlkeSI?si=VYgZig0sLae7Wpbx
0 · Reply
biotechdeeppro
biotechdeeppro Jun. 12 at 9:13 PM
$ALMS , what happened?
0 · Reply
jledet
jledet Jun. 12 at 2:05 PM
$ALMS
0 · Reply
forprofit12
forprofit12 Jun. 9 at 3:19 PM
$ALMS added. Will add more as funds become available
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jun. 9 at 4:06 AM
$ALMS $TERN $GPCR smart people follow the money.
0 · Reply
IN0V8
IN0V8 Jun. 8 at 7:11 PM
$ALMS Added at $19
0 · Reply
IN0V8
IN0V8 Jun. 5 at 5:03 PM
$ALMS Sold a Small LT position at $19.47 / +142% gain, I still maintain a good long position and will double the amount of shares that I sold when I buy it back at $19 or less.
0 · Reply
Poester
Poester Jun. 3 at 3:40 PM
$ALMS Am adding more to my position right now, as we've hit a double bottom in the high 19's.
0 · Reply